Achillion Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
IMMUImmunomedics, Inc. -0.27%85.2911.0%$738.78m
MRNAModerna, Inc. 0.03%70.570.0%$682.07m
AMGNAmgen, Inc. -0.35%246.161.3%$661.89m
ILMNIllumina, Inc. -0.09%305.183.5%$633.00m
NVAXNovavax, Inc. -3.92%106.8296.5%$612.60m
GILDGilead Sciences, Inc. -1.11%62.151.0%$580.91m
REGNRegeneron Pharmaceuticals, Inc. -0.28%570.342.7%$448.89m
BIIBBiogen, Inc. 0.50%283.451.6%$357.89m
VRTXVertex Pharmaceuticals, Inc. 0.88%270.081.9%$351.26m
SRNESorrento Therapeutics, Inc. 18.82%12.061.5%$303.27m
ALXNAlexion Pharmaceuticals, Inc. -0.59%112.632.0%$289.07m
EXASEXACT Sciences Corp. 1.25%100.9520.7%$269.57m
SGENSeattle Genetics, Inc. 0.35%191.186.0%$227.17m
VXRTVaxart, Inc. -0.93%6.940.0%$209.20m
MNTAMomenta Pharmaceuticals, Inc. 0.03%52.483.0%$181.41m

Company Profile

At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.